20 May 2020

Covis Pharma has launched a Phase III clinical trial to evaluate its asthma drug Alvesco (ciclesonide) for the treatment of non-hospitalised, symptomatic Covid-19 patients aged 12 years and above. The company secured the US Food and Drug Administration (FDA) approval to conduct the trial. Alvesco is also being studied in Covid-19 in Australia, Japan, South Korea, Sweden and the UK, among others.

A team involving researchers from Beijing Advanced Innovation Center for Genomics (ICG) at Peking University (PKU) has identified various antibodies with neutralising activity against Covid-19. Based on findings from animal studies, the researchers claim that their neutralising antibody could offer a potential cure and also short-term prevention for the disease.

Australian researchers, led by the Walter and Eliza Hall Institute of Medical Research, have launched a clinical trial to assess hydroxychloroquine for the prevention of Covid-19 in around 2,250 high risk healthcare workers. Named COVID SHIELD the trial will run for four months.

Aetion has entered into a research collaboration agreement with the US Food and Drug Administration (FDA) to use real-world data to gain better insights regarding the course and treatment of Covid-19. The partners will find and analyse fit-for-purpose data sources to characterise patient populations and their medication use.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.